Viking Therapeutics to Report Financial Results for Third Quarter 2024 on October 23, 2024
10 Health Care Stocks With Whale Alerts In Today's Session
Where Will Viking Therapeutics Be in 5 Years?
Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics Vs. Summit Therapeutics
With 74% Institutional Ownership, Viking Therapeutics, Inc. (NASDAQ:VKTX) Is a Favorite Amongst the Big Guns
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market
Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years
Maxim Group Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $120
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $90 to $125
Analysts' Opinions Are Mixed on These Healthcare Stocks: Sanofi (OtherSNYNF) and Viking Therapeutics (VKTX)
Buy Rating Affirmed for Viking Therapeutics on Promising VK0214 and VK2735 Clinical Data
Viking Therapeutics Reveals Encouraging Data From Genetic Disorder Drug Study, Analyst Says Focus On Orphan Disease Broadens Viking's Potential Revenue Streams
Express News | HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $90 Price Target
Sector Update: Health Care Stocks Steady Pre-Bell Wednesday
Viking Therapeutics' Stock Pops on News of Positive Data From Trial of Treatment for Rare Metabolic Disorder X-ALD
Express News | Viking Therapeutics: One Subject in Placebo Cohort Experienced a Wrist Fracture That Was Characterized as a Severe Adverse Event in Vk0214 Study
Express News | Viking Therapeutics Inc - Significant Reductions in Vlcfas and Other Lipids Observed
Express News | Viking Therapeutics Inc - Vk0214 Shown to Be Safe and Well-Tolerated in 28-Day Study